drugset / Trial / NCT01063439
BuEAM Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat Diffuse Large B Cell Lymphoma (DLCBL)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and toxicity of busulfan, etoposide, cytarabine and melphalan (BuEAM) including intravenous busulfan instead of BCNU of standard BEAM as a conditioning for autologous stem cell transplantation in patients with NHL.
Timeline
- Start
- 2010-01
- Primary completion
- 2014-08
- Completion
- 2015-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Busulfan | Small molecule | 3.2 mg/kg | Intravenous |
| Subject | Cytarabine | Small molecule | 1 g | — |
| Subject | Etoposide | Small molecule | 400 mg/m2 | — |
| Subject | Melphalan | Small molecule | 140 mg/m2 | — |